Active Ingredient(s): Ranibizumab
FDA Approved: * October 22, 2021
Pharm Company: * GENENTECH INC
Category: Vision / Eye Health

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Susvimo Overview

Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic[6] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, an...

Read more Susvimo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Susvimo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 0, 0.5mg(10mg/ml), 10mg/ml
  • Solution: 100mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Susvimo: (1 result)

Sorted by National Drug Code
  • 50242-078 Susvimo 100 mg/ml Intravitreal Injection, Solution by Genentech, Inc.

Other drugs which contain Ranibizumab or a similar ingredient: (3 results)